Insights from the AQUA Registry: a retrospective study of anticholinergic polypharmacy in the United States

Matthew R Cooperberg; Rachel Mbassa; David Walker; William Meeks; Amy Lockefeer; Baoguo Jiang; Tina Li; Karissa Johnston; Raymond Fang

doi:10.1177/17562872221150572

Insights from the AQUA Registry: a retrospective study of anticholinergic polypharmacy in the United States

Ther Adv Urol. 2023 Jan 19:15:17562872221150572. doi: 10.1177/17562872221150572. eCollection 2023 Jan-Dec.

Authors

Matthew R Cooperberg^{1

2}, Rachel Mbassa², David Walker³, William Meeks², Amy Lockefeer⁴, Baoguo Jiang⁵, Tina Li⁶, Karissa Johnston⁶, Raymond Fang²

Affiliations

¹ Departments of Urology and Epidemiology & Biostatistics, University of California, San Francisco, CA, USA.
² American Urological Association, Linthicum, MD, USA.
³ Astellas Pharma Global Development Inc., Northbrook, IL, 60062, USA.
⁴ Astellas Pharma Global Development Inc., Northbrook, IL, USA.
⁵ Astellas Pharma US, Inc., Northbrook, IL, USA.
⁶ Broadstreet Health Economics and Outcomes Research, Vancouver, BC, Canada.

Abstract

Background: Anticholinergic (ACH) burden is a risk factor for negative health outcomes among older adults. Several medications contribute to ACH burden, including antimuscarinics used to manage overactive bladder (OAB).

Objectives: This study aimed to understand the extent of ACH burden in an OAB population in the United States.

Design: Non-interventional retrospective analysis.

Methods: Adults with OAB whose care providers participated in the American Urological Association Quality (AQUA) Registry between 2014 and 2020 were included in this study. An adapted version of the Pharmacy Quality Alliance (PQA) measure of anticholinergic polypharmacy (poly-ACH) was used to assess ACH burden. The primary outcome was the annual prevalence of poly-ACH, and a secondary outcome was the percentage of patients taking 0, 1, 2, 3, 4, or ⩾ 5 ACH medications by calendar year. Analyses were stratified by age category at diagnosis and sex.

Results: The sample comprised 552,840 patients with OAB. The mean age at initial OAB diagnosis was 65.7 years (58.2% male; 57.4% white). Prevalence of poly-ACH was highest in 2015 (3.7%) and lowest in 2020 (1.9%). Patients prescribed no ACH medications made up the largest proportion of each cohort, while those prescribed five or more comprised the smallest. The trend of decreasing proportions of patients taking increasing numbers of ACH medications was consistent. The proportion of patients prescribed no ACH medications increased from 63.3% in 2014 to 74.6% in 2020. The percentage of those prescribed three or more ACHs remained largely unchanged. Poly-ACH was highest among younger individuals (< 65 years of age) and females; temporal trends were similar overall and within each age and sex stratum.

Conclusion: In this study, poly-ACH in patients with OAB was relatively infrequent and decreased over the study period. Further evaluation of poly-ACH is needed to assess whether the study findings reflect increased awareness of the negative effects of poly-ACH.

Keywords: anticholinergic burden; observational study; overactive bladder; polypharmacy.